Investors in uniQure N.V. (QURE) Can Take Lead in Securities Fraud Class Action Lawsuit

Investors who have invested in uniQure N.V. (NASDAQ: QURE) during the period between September 24, 2025, and October 31, 2025, now have the opportunity to participate in a securities fraud class-action lawsuit. The law firm Kessler Topaz Meltzer & Check, LLP has taken action on behalf of investors who bought or acquired uniQure shares during this specified Class Period. The lawsuit, known as Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, has been filed in the United States District Court for the Southern District of New York.

Investors who fall within the Class Period are urged to take note of the important deadline, which is due by April 13, 2026. They have the chance to seek appointment as lead plaintiff for the class by contacting Kessler Topaz Meltzer & Check, LLP (KTMC). Those who have incurred losses related to their uniQure investment can reach out to attorney Jonathan Naji, Esq. via phone at (484) 270-1453 or email at [email protected].

uniQure N.V. is involved in the development of gene therapies for rare diseases, with a focus on Huntington’s disease (HD). The company, headquartered in Amsterdam, Netherlands, has been working on their leading drug candidate, AMT-130, a gene therapy aimed at slowing the progression of HD. HD is a deadly, hereditary genetic disorder that affects the nerve cells in the brain, resulting in movement and cognitive problems, as well as psychiatric issues. Currently, there are no approved treatments for slowing down the progression of HD, making AMT-130 a significant potential breakthrough in the field.

In 2022, uniQure finished enrolling patients for two Phase I/II clinical trials of AMT-130, known as the Pivotal Phase I/II Study. This study aimed to assess the drug’s effectiveness in treating patients with HD. During calls with investors in June and July 2025, uniQure’s CEO, Matthew Kapusta, assured investors about the positive alignment between the company and the FDA regarding the study’s design.

The Class Period commenced on September 24, 2025, when uniQure released topline results from the Pivotal Study. These results, particularly focusing on the reduction of cerebrospinal neurofilament light protein (CSF NfL), were highlighted as a positive outcome suggesting that AMT-130 was effective in slowing neurodegeneration in patients with HD. Investor confidence was boosted, and uniQure’s share price soared from $13.66 on September 23, 2025, to $47.50 per share on September 24, 2025, representing a significant increase of nearly 250%. By October 29, 2025, the share price had surged further, trading at over $70.00 per share.

The encouraging study results and positive statements made by uniQure’s executives fuelled expectations of accelerated FDA approval for AMT-130. Investors were led to believe that there was a high probability of accelerated approval following the company’s planned submission of a Biologics License Application (BLA) in the first quarter of 2026. As a result, the market reacted positively to these developments, causing a substantial rise in uniQure’s share price during the Class Period.